Pre-clinical drug prioritization via prognosis-guided genetic interaction networks

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Xiong, Jianghui ^a,b   Liu, Juan ^a   Rayner, Simon ^c   Tian, Ze ^d   Li, Yinghui ^b   Chen, Shanguang ^b  

^a WUHAN UNIVERSITY   (China)

^b Center of Bioinformatics   (China)

^c WUHAN INSTITUTE OF VIROLOGY   (China)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CARBOPLATIN; CISPLATIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; PACLITAXEL; RAPAMYCIN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COMPUTER MODEL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; DRUG SENSITIVITY; EPIGENETICS; GENE CLUSTER; GENE CONSTRUCT; GENE EXPRESSION; GENE INTERACTION; LUNG NON SMALL CELL CANCER; OUTCOME ASSESSMENT; PROGNOSIS; SYNERGISTIC OUTCOME DETERMINATION; ANIMAL; BIOLOGICAL MODEL; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; GENETIC HETEROGENEITY; GENETICS; HUMAN; NEOPLASM; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; GENETIC HETEROGENEITY; HUMANS; MODELS, GENETIC; NEOPLASMS; PROGNOSIS;

EID: 78649729132     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013937     Document Type: Article

References (49)

1. Kamb A (2005) What's wrong with our cancer models? Nat Rev Drug Discov 4: 161-165.
2. Jones D (2009) Avastin-Tarceva combination fails in lung cancer. Nat Biotechnol 27: 108-109.
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659-1672.
4. Radiloff DR, Rinella ES, Threadgill DW (2008) Modeling cancer patient populations in mice: complex genetic and environmental factors. Drug Discov Today Dis Models 4: 83-88.
5. Network CGAR (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
6. Hopkins AL (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4: 682-690.
7. Yildirim MA, Goh KI, Cusick ME, Barabasi AL, Vidal M (2007) Drug-target network. Nat Biotechnol 25: 1119-1126.
8. Kitano H (2007) A robustness-based approach to systems-oriented drug design. Nat Rev Drug Discov 6: 202-210.
9. Csermely P, Agoston V, Pongor S (2005) The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 26: 178-182.
10. Kaelin WG, Jr. (2005) The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5: 689-698.
11. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, et al. (2009) Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers. N Engl J Med.
12. Whitehurst AW, Bodemann BO, Cardenas J, Ferguson D, Girard L, et al. (2007) Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446: 815-819.
13. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
14. Watkinson J, Wang X, Zheng T, Anastassiou D (2008) Identification of gene interactions associated with disease from gene expression data using synergy networks. BMC Syst Biol 2: 10.
15. Taylor IW, Linding R, Warde-Farley D, Liu Y, Pesquita C, et al. (2009) Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat Biotechnol 27: 199-204.
16. Chuang HY, Lee E, Liu YT, Lee D, Ideker T (2007) Network-based classification of breast cancer metastasis. Mol Syst Biol 3: 140.
17. Kitano H (2004) Biological robustness. Nat Rev Genet 5: 826-837.
18. Janne PA, Gray N, Settleman J (2009) Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 8: 709-723.
19. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929-1935.
20. Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6: 813-823.
21. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, et al. (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24: 236-244.
22. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58.
23. Kemper C, Atkinson JP (2007) T-cell regulation: with complements from innate immunity. Nat Rev Immunol 7: 9-18.
24. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, et al. (2008) Modulation of the antitumor immune response by complement. Nat Immunol 9: 1225-1235.
25. Feinberg AP, Ohlsson R, Henikoff S (2006) The epigenetic progenitor origin of human cancer. Nat Rev Genet 7: 21-33.
26. Feinberg AP (2007) Phenotypic plasticity and the epigenetics of human disease. Nature 447: 433-440.
27. Newman ME (2006) Modularity and community structure in networks. Proc Natl Acad Sci U S A 103: 8577-8582.
28. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ (2008) MiRBase: tools for microRNA genomics. Nucleic Acids Res 36: D154-158.
29. DeVita VT, Hellman S, Rosenberg SA (1989) Cancer: principles & practice of oncology. Philadelphia: Lippincott. 2489, 2464 p.
30. Hoeller D, Dikic I (2009) Targeting the ubiquitin system in cancer therapy. Nature 458: 438-444.
31. Davies AM, Chansky K, Lara PN, Jr., Gumerlock PH, Crowley J, et al. (2009) Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J Thorac Oncol 4: 87-92.
32. Nalepa G, Rolfe M, Harper JW (2006) Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov 5: 596-613.
33. Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, et al. (2004) The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther 3: 279-290.
34. Suh MR, Lee Y, Kim JY, Kim SK, Moon SH, et al. (2004) Human embryonic stem cells express a unique set of microRNAs. Dev Biol 270: 488-498.
35. Wu M, Jung L, Cooper AB, Fleet C, Chen L, et al. (2009) Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice. Proc Natl Acad Sci U S A 106: 7022-7027.
36. Birney E, Stamatoyannopoulos JA, Dutta A, Guigo R, Gingeras TR, et al.(2007) Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447: 799-816.
37. Holland AJ, Cleveland DW (2009) Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nat Rev Mol Cell Biol 10: 478-487.
38. Brock A, Chang H, Huang S (2009) Non-genetic heterogeneity-a mutation-independent driving force for the somatic evolution of tumours. Nat Rev Genet 10: 336-342.
39. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51.
40. Ruepp A, Brauner B, Dunger-Kaltenbach I, Frishman G, Montrone C, et al.(2008) CORUM: the comprehensive resource of mammalian protein complexes. Nucleic Acids Res 36: D646-650.
41. Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, et al. (2006) A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 355: 570-580.
42. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, et al. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679.
43. Bild AH, Yao G, Chang JT, Wang Q, Potti A, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357.
44. Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J, et al. (2008) An 86-probe-set gene-expression signature predicts survival in cytoge-netically normal acute myeloid leukemia. Blood 112: 4193-4201.
45. Anastassiou D (2007) Computational analysis of the synergy among multiple interacting genes. Mol Syst Biol 3: 83.
46. Clegg A, Scott DA, Hewitson P, Sidhu M, Waugh N (2002) Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review. Thorax 57: 20-28.
47. Provencio M, Sanchez A, Garrido P, Valcarcel F (2010) New molecular targeted therapies integrated with radiation therapy in lung cancer. Clin Lung Cancer 11: 91-97.
48. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, et al. (2004) The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 91: 355-358.
49. Lauss M, Visne I, Weinhaeusel A, Vierlinger K, Noehammer C, et al. (2008) MethCancerDB-aberrant DNA methylation in human cancer. Br J Cancer 98: 816-817.